SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Treasury Stock, Receivables and Deferred Revenue (Details) - USD ($)		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Treasury Stock [Abstract]
Treasury stock purchased (in shares)		11,387	51,331
Average price of share (in dollars per share)		$ 54.51	$ 58.45
Receivables [Abstract]
Accounts receivable		$ 19,065,919	$ 16,518,687
Deferred Revenue [Abstract]
Deferred revenue		0	0
ASU 2014-09 [Member]
Deferred Revenue, Recognized [Abstract]
Remaining performance obligations recognized during period			0
Adjustments / Effect of Change Higher / (Lower) [Member] | ASU 2014-09 [Member]
Receivables [Abstract]
Accounts receivable			9,700,000
Nonrefundable Upfront Product License Fees [Member]
Deferred Revenue, Recognized [Abstract]
Deferred revenue, recognized			35,000
Milestone Payment Due Foreign Tax Withholding [Member]
Deferred Revenue [Abstract]
Deferred revenue			0
Provision for receivable uncollectable			100,000
Endo [Member]
Receivables [Abstract]
Accounts receivable		$ 19,100,000	$ 16,500,000	$ 4,700,000
Deferred Revenue [Abstract]
Deferred revenue				(6,400,000)
Endo [Member] | ASU 2014-09 [Member]
Receivables [Abstract]
Accounts receivable				12,300,000
Deferred Revenue [Abstract]
Deferred revenue				(100,000)
Endo [Member] | Adjustments / Effect of Change Higher / (Lower) [Member] | ASU 2014-09 [Member]
Receivables [Abstract]
Accounts receivable	[1]			7,600,000
Deferred Revenue [Abstract]
Deferred revenue	[2]			$ 6,300,000

[1] This adjustment represents the elimination of the one quarter lag by recognizing royalty revenues based on of XIAFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.

[2] Represents the remaining deferred revenue balance of the prepaid mark-up on cost of goods sold based on sales by non-affiliated sublicensees of Endo outside of the U.S.